MarketCap
Facebook
X
Telegram
Diffusion Pharmaceuticals Balance Sheet 2025-2010 | DFFN
Brief overview of Diffusion Pharmaceuticals 's assets and capital
The review uses the five latest available annual reports between 2020 and 2025.
Assets declined from $27.7 million to $22.9 million, or -17.5%. The contraction calls for context such as disposals, restructuring or weaker operations.
Liability growth of +59.7% exceeded asset growth of -17.5%, increasing reliance on outside funding.
Internal capital represents 79.6% of the balance sheet, previously 89.5%. This is a strong capital position.
Cash represents 36% of assets versus 66.8% initially, showing how the immediate liquidity reserve changed.
Retained earnings remain negative at -$97.7 million. This may reflect past losses or substantial shareholder distributions, so earnings and buybacks provide important context.
Conclusion
Diffusion Pharmaceuticals 's financial structure calls for caution. Stronger equity, lower debt or restored liquidity would be needed to improve it.
Annual Balance Sheet Diffusion Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | - | - | - | - | -17.9 M | -13.9 M | -7.99 M | -8.35 M | 877 K | -19.2 M | -21.9 M | 1.61 M | 3.69 M | 590 K | - |
Long Term Debt |
- | - | - | - | - | 35.7 K | - | - | - | 550 K | - | - | - | - | - | - |
Long Term Debt Current |
- | - | - | - | - | 113 K | 111 K | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | 480 K | 2.25 M | 1.79 M | 2.23 M | 3.86 M | - | 2.27 M | 3 M | - | - | - |
Total Current Liabilities |
4.66 M | 3.88 M | - | - | - | 2.44 M | 1.72 M | 804 K | 2.69 M | 4.44 M | 1.2 M | 2.34 M | 8.88 M | 20.9 M | 3.79 M | 4.93 M |
Total Liabilities |
4.66 M | 3.88 M | 2.6 M | 13.2 M | 2.93 M | 2.92 M | 3.98 M | 2.59 M | 4.92 M | 8.3 M | 4.37 M | 4.61 M | 11.9 M | 20.9 M | 3.79 M | 5.56 M |
Deferred Revenue |
- | - | - | - | - | 444 K | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-97.7 M | -70.7 M | -54.4 M | -52.3 M | -130 M | -106 M | -91.7 M | -79.9 M | -61.6 M | -60.2 M | -78.8 M | -75.3 M | -60.9 M | -56.7 M | -42.1 M | - |
Total Assets |
22.9 M | 43.1 M | 9.97 M | 4.16 M | 37.8 M | 27.7 M | 24.1 M | 18.2 M | 26.1 M | 17.5 M | 39.6 M | 42.8 M | 18.3 M | 2.45 M | 3.67 M | 5.58 M |
Cash and Cash Equivalents |
8.24 M | 9 M | 7.79 M | 4.09 M | 37.3 M | 18.5 M | 14.2 M | 7.99 M | 8.9 M | 1.55 M | 2 M | 21.9 M | 255 K | 312 K | 98.4 K | - |
Book Value |
18.2 M | 39.2 M | 7.38 M | -9 M | 34.9 M | 24.8 M | 20.1 M | 15.6 M | 21.2 M | 9.18 M | 35.3 M | 38.2 M | 6.47 M | -18.4 M | -113 K | 20.2 K |
Total Shareholders Equity |
18.2 M | 39.2 M | 7.38 M | -33.3 M | 34.9 M | 24.8 M | 20.1 M | 15.6 M | 21.2 M | 9.18 M | -41.6 K | 38.2 M | 6.46 M | -18.4 M | -16 M | - |
All numbers in USD currency
Quarterly Balance Sheet Diffusion Pharmaceuticals
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.82 K | 35.7 K | 35.7 K | 35.7 K | 35.7 K | 136 K | 136 K | 136 K | 136 K | - | - | - | - | - | - | - | 550 K | 550 K | 550 K | 550 K | 550 K | 819 K | 819 K | 819 K | 819 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
3.03 M | 4.5 M | 4.6 M | 4.64 M | 3.94 M | 3.88 M | 3.25 M | 3.21 M | 2.66 M | 2.6 M | 2.46 M | 14.2 M | 2.13 M | 13.2 M | - | - | - | 2.93 M | 2.75 M | 2.54 M | 2.57 M | 2.92 M | 2.92 M | 2.92 M | 2.92 M | 3.98 M | 3.98 M | 3.98 M | 3.98 M | 2.59 M | 2.59 M | 2.59 M | 2.59 M | 4.92 M | 4.92 M | 4.92 M | 4.92 M | 8.3 M | 8.3 M | 8.3 M | 8.3 M | 2.32 M | 2.32 M | 2.32 M | 2.32 M | 4.61 M | 4.61 M | 4.61 M | 4.61 M | 11.9 M | 11.9 M | 11.9 M | - | - | - | - | - | 3.79 M | 3.96 M | 3.81 M | - |
Deferred Revenue |
- | - | - | - | - | - | - | 1.4 M | 572 K | - | 547 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-112 M | -106 M | -89.6 M | -81.9 M | -75.6 M | -70.7 M | -64 M | -59.3 M | -57 M | -54.4 M | -52.1 M | -54.2 M | -52.8 M | -52.3 M | -142 M | -139 M | -135 M | -130 M | -127 M | -114 M | -111 M | -106 M | -106 M | -106 M | -106 M | -91.7 M | -91.7 M | -91.7 M | -91.7 M | -79.9 M | -79.9 M | -79.9 M | -79.9 M | -61.6 M | -61.6 M | -61.6 M | -61.6 M | -60.2 M | -60.2 M | -60.2 M | -60.2 M | -42.2 M | -42.2 M | -42.2 M | -42.2 M | -75.3 M | -75.3 M | -75.3 M | -75.3 M | -60.9 M | -60.9 M | -60.9 M | -60.9 M | -56.7 M | -56.7 M | -56.7 M | -56.7 M | -49.4 M | -42.2 M | -42.2 M | - |
Total Assets |
26 M | 15.1 M | 30.6 M | 38.1 M | 38.6 M | 43.1 M | 48.9 M | 53.2 M | 8 M | 9.97 M | 12 M | 3.36 M | 3.94 M | 4.16 M | 26.3 M | 29.2 M | 33.6 M | 37.8 M | 40.9 M | 52.7 M | 56.2 M | 27.7 M | 27.7 M | 27.7 M | 27.7 M | 24.1 M | 24.1 M | 24.1 M | 24.1 M | 18.2 M | 18.2 M | 18.2 M | 18.2 M | 26.1 M | 26.1 M | 26.1 M | 26.1 M | 17.5 M | 17.5 M | 17.5 M | 17.5 M | 2.28 M | 2.28 M | 2.28 M | 2.28 M | 42.8 M | 42.8 M | 42.8 M | 42.8 M | 18.3 M | 18.3 M | 18.3 M | 18.3 M | 2.45 M | 2.45 M | 2.45 M | 2.45 M | 3.67 M | 3.67 M | 3.67 M | - |
Cash and Cash Equivalents |
22.5 M | 7.94 M | 9.44 M | 8.32 M | 10.5 M | 9 M | 7.74 M | 10 M | 6.37 M | 7.79 M | 10.4 M | 650 K | 2.61 M | 4.09 M | 4.79 M | 5.97 M | 9.87 M | 37.3 M | 40.3 M | 43.3 M | 46.6 M | 18.5 M | 18.5 M | 18.5 M | 18.5 M | 14.2 M | 14.2 M | 14.2 M | 14.2 M | 7.99 M | 7.99 M | 7.99 M | 7.99 M | 8.9 M | 8.9 M | 8.9 M | 8.9 M | 1.55 M | 1.55 M | 1.55 M | 1.55 M | 2 M | 2 M | 2 M | 2 M | 2.34 M | 21.9 M | 21.9 M | 21.9 M | 255 K | 255 K | 255 K | 255 K | 312 K | 312 K | 312 K | 312 K | 98.4 K | 98.4 K | 98.4 K | - |
Book Value |
23 M | 10.6 M | 26 M | 33.4 M | 34.6 M | 39.2 M | 45.6 M | 50 M | 5.34 M | 7.38 M | 9.57 M | -10.8 M | 1.82 M | -9 M | 26.3 M | 29.2 M | 33.6 M | 34.9 M | 38.1 M | 50.2 M | 53.6 M | 24.8 M | 24.8 M | 24.8 M | 24.8 M | 20.1 M | 20.1 M | 20.1 M | 20.1 M | 15.6 M | 15.6 M | 15.6 M | 15.6 M | 21.2 M | 21.2 M | 21.2 M | 21.2 M | 9.18 M | 9.18 M | 9.18 M | 9.18 M | -41.6 K | -41.6 K | -41.6 K | -41.6 K | 38.2 M | 38.2 M | 38.2 M | 38.2 M | 6.47 M | 6.47 M | 6.47 M | 18.3 M | 2.45 M | 2.45 M | 2.45 M | 2.45 M | -113 K | -289 K | -140 K | - |
Total Shareholders Equity |
23 M | 10.6 M | 26 M | 33.4 M | 34.6 M | 39.2 M | 45.6 M | 50 M | 5.34 M | 7.38 M | 9.57 M | -35.1 M | -33.7 M | -33.3 M | -31.8 M | 26.7 M | 30.6 M | 34.9 M | 38.1 M | 50.2 M | 53.6 M | 24.8 M | 24.8 M | 24.8 M | 24.8 M | 20.1 M | 20.1 M | 20.1 M | 20.1 M | 15.6 M | 15.6 M | 15.6 M | 15.6 M | 21.2 M | 21.2 M | 21.2 M | 21.2 M | 9.18 M | 9.18 M | 9.18 M | 9.18 M | -41.6 K | -41.6 K | -41.6 K | -41.6 K | 38.2 M | 42.8 M | 45.3 M | 12.2 M | 6.46 M | 6.46 M | 6.46 M | 6.46 M | -18.4 M | -18.4 M | -18.4 M | -18.4 M | -16.1 M | -143 K | -143 K | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Diffusion Pharmaceuticals , providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Canada
China
Israel
France
Germany
Britain
Russia
Belgium
Cayman-islands
